Why the study?
Does oxygen supplementation increase systemic vascular resistance and blood pressure in patients with chronic kidney disease?
Does oxygen supplementation increase systemic vascular resistance and blood pressure in patients with chronic kidney disease?
Oxygen supplementation in CKD patients causes a non-baroreflex mediated increase in systemic vascular resistance and blood pressure, suggesting it may act as a cardiovascular stressor.
May caution against oxygen for BP lowering in CKD; leaves open hyperoxia-SVR mechanisms in prospective trials.
Renal hypoxia is thought to be an important pathophysiological factor in the progression of chronic kidney disease (CKD) and the associated hypertension. In a previous study among CKD patients, supplementation with 100% oxygen reduced sympathetic nerve activity (SNA) and lowered blood pressure (BP). We aimed to assess the underlying haemodynamic modulation and hypothesized a decreased systemic vascular resistance (SVR). To that end, 19 CKD patients were studied during 15-minute intervals of increasing partial oxygen pressure (ppO2) from room air (0.21 ATA) to 1.0 ATA and further up to 2.4 ATA, while continuously measuring finger arterial blood pressure (Finapres). Off-line, we derived indexes of SVR, cardiac output (CO) and baroreflex sensitivity from the continuous BP recordings (Modelflow). During oxygen supplementation, systolic and diastolic BP both increased dose-dependently from 128±24 and 72±19 mmHg respectively at baseline to 141±23 (p<0.001) and 80±21 mmHg (p<0.001) at 1.0ATA oxygen. Comparing baseline and 1.0 ATA oxygen, SVR increased from 1440±546 to 1745±710dyn·s/cm5 (p=0.009), heart rate decreased from 60±8 to 58±6 bpm (p<0.001) and CO from 5.0±1.3 to 4.6±1.1 L/min (p=0.02). Baroreflex sensitivity remained unchanged (13±13 to 15±12 ms/mmHg). These blood pressure effects were absent in a negative control group of eight young healthy subjects. We conclude that oxygen supplementation in CKD patients causes a non-baroreflex mediated increased in SVR and blood pressure.
No takes yet. Share an insight, caveat, or question.
Bel et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: